CN102112146B - 免疫诱导剂 - Google Patents

免疫诱导剂 Download PDF

Info

Publication number
CN102112146B
CN102112146B CN200980130313.6A CN200980130313A CN102112146B CN 102112146 B CN102112146 B CN 102112146B CN 200980130313 A CN200980130313 A CN 200980130313A CN 102112146 B CN102112146 B CN 102112146B
Authority
CN
China
Prior art keywords
polypeptide
cells
seq
cancer
immunity
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN200980130313.6A
Other languages
English (en)
Chinese (zh)
Other versions
CN102112146A (zh
Inventor
冈野文义
清水正树
斋藤孝则
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Toray Industries Inc
Original Assignee
Toray Industries Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Toray Industries Inc filed Critical Toray Industries Inc
Priority to CN201410047289.2A priority Critical patent/CN103751771B/zh
Publication of CN102112146A publication Critical patent/CN102112146A/zh
Application granted granted Critical
Publication of CN102112146B publication Critical patent/CN102112146B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CN200980130313.6A 2008-08-05 2009-08-05 免疫诱导剂 Active CN102112146B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201410047289.2A CN103751771B (zh) 2008-08-05 2009-08-05 免疫诱导剂

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2008202065 2008-08-05
JP202065/2008 2008-08-05
PCT/JP2009/063881 WO2010016525A1 (ja) 2008-08-05 2009-08-05 免疫誘導剤

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201410047289.2A Division CN103751771B (zh) 2008-08-05 2009-08-05 免疫诱导剂

Publications (2)

Publication Number Publication Date
CN102112146A CN102112146A (zh) 2011-06-29
CN102112146B true CN102112146B (zh) 2014-03-12

Family

ID=41663742

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201410047289.2A Active CN103751771B (zh) 2008-08-05 2009-08-05 免疫诱导剂
CN200980130313.6A Active CN102112146B (zh) 2008-08-05 2009-08-05 免疫诱导剂

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CN201410047289.2A Active CN103751771B (zh) 2008-08-05 2009-08-05 免疫诱导剂

Country Status (16)

Country Link
US (2) US8454968B2 (enExample)
EP (2) EP2324842B1 (enExample)
JP (2) JP5691171B2 (enExample)
KR (3) KR101669827B1 (enExample)
CN (2) CN103751771B (enExample)
AU (2) AU2009278385B2 (enExample)
BR (2) BR122020027042B1 (enExample)
CA (1) CA2732283C (enExample)
DK (2) DK2837383T3 (enExample)
ES (2) ES2539603T3 (enExample)
HU (1) HUE031343T2 (enExample)
MX (2) MX339277B (enExample)
PL (2) PL2324842T3 (enExample)
PT (2) PT2324842E (enExample)
RU (2) RU2511039C2 (enExample)
WO (1) WO2010016525A1 (enExample)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5644110B2 (ja) * 2008-08-05 2014-12-24 東レ株式会社 癌の検出方法
RU2498819C2 (ru) 2008-08-05 2013-11-20 Торэй Индастриз, Инк. Фармацевтическая композиция для лечения и профилактики злокачественных опухолей
RU2607366C2 (ru) 2010-02-04 2017-01-10 Торэй Индастриз, Инк. Фармацевтическая композиция для лечения и/или профилактики рака
KR101843807B1 (ko) * 2010-02-04 2018-03-30 도레이 카부시키가이샤 암의 치료 및/또는 예방을 위한 의약품
MX342291B (es) * 2010-02-04 2016-09-23 Toray Industries Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
EP2532743B1 (en) 2010-02-04 2015-04-15 Toray Industries, Inc. Pharmaceutical composition for treatment and/or prevention of cancer
ES2583777T3 (es) 2010-02-04 2016-09-22 Toray Industries, Inc. Composición farmacéutica que comprende anticuerpos anti CAPRIN-1 para el tratamiento y/o la prevención del cáncer
DK2532680T3 (da) * 2010-02-04 2015-07-20 Toray Industries Medicinsk sammensætning til behandling og/eller forebyggelse af cancer
EP2711017B1 (en) * 2011-05-19 2016-08-03 Toray Industries, Inc. Immunity inducing agent
PT2740793T (pt) * 2011-08-04 2018-02-23 Toray Industries Composição de fármacos para o tratamento e/ou a prevenção de cancro
MX348578B (es) * 2011-08-04 2017-06-20 Toray Industries Composicion farmaceutica para el tratamiento y/o prevencion de cancer.
HUE030137T2 (en) * 2011-08-04 2017-04-28 Toray Industries Pharmaceutical preparation for the treatment and / or prevention of cancer
BR112014002608A2 (pt) 2011-08-04 2018-02-20 Toray Industries anticorpo ou seu fragmento que possui reatividade imunológica com um polipeptídeo caprin-1, composição farmacêutica e combinação farmacêutica de tratamento e/ou prevenção de câncer, dna e método de tratamento e/ou prevenção de câncer
PL2740798T3 (pl) 2011-08-04 2017-07-31 Toray Industries, Inc. Kompozycja leku do leczenia i/lub zapobiegania nowotworom
WO2013018886A1 (ja) 2011-08-04 2013-02-07 東レ株式会社 膵臓癌の治療及び／又は予防用医薬組成物
US9796775B2 (en) 2011-08-04 2017-10-24 Toray Industries, Inc. Method for detecting pancreatic cancer
WO2013125640A1 (ja) 2012-02-21 2013-08-29 東レ株式会社 癌の治療及び／又は予防用医薬組成物
PT2818483T (pt) 2012-02-21 2017-10-09 Toray Industries Composição medicinal para tratamento e/ou prevenção de cancro
IN2014KN01714A (enExample) 2012-02-21 2015-10-23 Toray Industries
RU2632645C2 (ru) 2012-02-21 2017-10-06 Торэй Индастриз, Инк. Фармацевтическая композиция для лечения и/или профилактики рака
HUE036425T2 (hu) * 2012-03-30 2018-07-30 Toray Industries Gyógyászati készítmény epehólyagrák kezelésére és/vagy megelõzésére
PL2832365T3 (pl) 2012-03-30 2018-04-30 Toray Industries, Inc. Kompozycja farmaceutyczna do leczenia i/lub zapobiegania nowotworowi wątroby
RU2646464C2 (ru) 2012-07-19 2018-03-05 Торэй Индастриз, Инк. Метод детекции рака
US9772332B2 (en) 2012-07-19 2017-09-26 Toray Industries, Inc. Method for detecting CAPRIN-1 in a biological sample
CN105452294B (zh) 2013-08-09 2019-08-02 东丽株式会社 癌的治疗和/或预防用药物组合物
US20180092967A1 (en) * 2015-04-30 2018-04-05 Toray Industries, Inc. Immunity-inducing agent
CN109890417A (zh) * 2016-10-28 2019-06-14 东丽株式会社 癌的治疗和/或预防用药物组合物
AU2019242520A1 (en) * 2018-03-30 2020-10-29 Toray Industries, Inc. Pharmaceutical composition for treatment and/or prevention of cancer
CN109206502B (zh) * 2018-09-26 2022-03-04 东北农业大学 一种猫干扰素ω及其制备方法和在抗病毒中的应用
CN109206501B (zh) * 2018-09-26 2022-03-04 东北农业大学 猫干扰素ω、其编码基因及其在抗病毒方面的应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1678338A (zh) * 2002-08-30 2005-10-05 株式会社免疫新领域 调控调节性t细胞活性的方法及组合物
WO2005116051A2 (de) * 2004-05-25 2005-12-08 Immatics Biotechnologies Gmbh An mhc-moleküle bindende tumor-assoziierte peptide
WO2008088583A2 (en) * 2006-08-30 2008-07-24 Immunotope, Inc Cytotoxic t-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA56132C2 (uk) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
US5698396A (en) 1995-06-07 1997-12-16 Ludwig Institute For Cancer Research Method for identifying auto-immunoreactive substances from a subject
TW200728465A (en) * 1998-07-14 2007-08-01 Corixa Corp Compositions and methods for the therapy and diagnosis of prostate cancer
WO2002083070A2 (en) * 2001-04-10 2002-10-24 Corixa Corporation Compounds for immunotherapy and diagnosis of colon cancer and methods for their use
US20030190640A1 (en) 2001-05-31 2003-10-09 Mary Faris Genes expressed in prostate cancer
JP4533626B2 (ja) * 2001-11-07 2010-09-01 サイトス バイオテクノロジー アーゲー アレルギー性好酸球性疾患を治療するための抗原アレイ
US20050003390A1 (en) * 2002-05-17 2005-01-06 Axenovich Sergey A. Targets for controlling cellular growth and for diagnostic methods
WO2005100998A2 (en) 2004-04-16 2005-10-27 Europroteome Ag Membrane markers for use in cancer diagnosis and therapy
EP1991701A4 (en) 2006-02-14 2010-03-17 Dana Farber Cancer Inst Inc COMPOSITIONS, KITS AND METHODS OF IDENTIFICATION, ASSESSMENT, PREVENTION AND THERAPY OF CANCER
KR20080075722A (ko) 2007-02-13 2008-08-19 엘지이노텍 주식회사 튜너
JP4826496B2 (ja) 2007-02-16 2011-11-30 三菱マテリアル株式会社 電解メッキ用アノード電極取付構造
WO2013143026A1 (en) * 2012-03-31 2013-10-03 Abmart (Shanghai) Co., Ltd Peptide and antibody libraries and uses thereof
WO2014197471A1 (en) * 2013-06-03 2014-12-11 Acetylon Pharmaceuticals, Inc. Histone deacetylase ( hdac) biomarkers in multiple myeloma

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1678338A (zh) * 2002-08-30 2005-10-05 株式会社免疫新领域 调控调节性t细胞活性的方法及组合物
WO2005116051A2 (de) * 2004-05-25 2005-12-08 Immatics Biotechnologies Gmbh An mhc-moleküle bindende tumor-assoziierte peptide
WO2008088583A2 (en) * 2006-08-30 2008-07-24 Immunotope, Inc Cytotoxic t-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
SEREX, Proteomex, AMIDA, and beyond:Serological screening technologies for target identification;Jens Rauch et al;《Proteomic Clinical Applications》;20080207;第2卷(第3期);355-371 *

Also Published As

Publication number Publication date
EP2324842A1 (en) 2011-05-25
JP5691171B2 (ja) 2015-04-01
MX2011001113A (es) 2011-03-04
CA2732283A1 (en) 2010-02-11
BRPI0912462A2 (enExample) 2016-02-02
EP2324842B1 (en) 2015-03-25
ES2619322T3 (es) 2017-06-26
CN103751771B (zh) 2017-09-08
DK2324842T3 (da) 2015-06-22
RU2511039C2 (ru) 2014-04-10
US9592281B2 (en) 2017-03-14
EP2324842A4 (en) 2012-05-23
MX339277B (es) 2016-05-19
PL2837383T3 (pl) 2017-07-31
JP5962739B2 (ja) 2016-08-03
KR102009241B1 (ko) 2019-08-09
KR20110044854A (ko) 2011-05-02
PT2324842E (pt) 2015-07-21
CN103751771A (zh) 2014-04-30
AU2009278385A1 (en) 2010-02-11
BR122020027042B1 (pt) 2022-11-08
ES2539603T3 (es) 2015-07-02
RU2639518C2 (ru) 2017-12-21
US20110123492A1 (en) 2011-05-26
RU2013156620A (ru) 2015-06-27
MX348464B (es) 2017-06-14
PL2324842T3 (pl) 2015-08-31
KR20170128637A (ko) 2017-11-22
CN102112146A (zh) 2011-06-29
RU2011108315A (ru) 2012-09-10
JPWO2010016525A1 (ja) 2012-01-26
AU2009278385B2 (en) 2015-06-11
EP2837383B1 (en) 2016-12-14
AU2015210461B2 (en) 2017-07-13
KR20160127146A (ko) 2016-11-02
BRPI0912462B1 (pt) 2022-03-22
KR101669827B1 (ko) 2016-10-27
US8454968B2 (en) 2013-06-04
PT2837383T (pt) 2017-03-17
EP2837383A1 (en) 2015-02-18
DK2837383T3 (en) 2017-03-20
JP2015061847A (ja) 2015-04-02
US20130230488A1 (en) 2013-09-05
AU2015210461A1 (en) 2015-09-03
WO2010016525A1 (ja) 2010-02-11
CA2732283C (en) 2017-12-05
HUE031343T2 (hu) 2017-07-28

Similar Documents

Publication Publication Date Title
CN102112146B (zh) 免疫诱导剂
KR101692819B1 (ko) 면역 유도제
US10463725B2 (en) Immunity inducing agent
AU2012256756B2 (en) Immunity induction agent
JP5217502B2 (ja) 癌の治療及び／又は予防剤
JP7160462B2 (ja) 免疫誘導剤
JP7087387B2 (ja) 免疫誘導剤
JP5572938B2 (ja) 免疫誘導剤
JPWO2017150595A1 (ja) 免疫誘導剤
JP2008247891A (ja) 癌の治療及び／又は予防剤

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant